Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer. (January 2018)

• Record Type: Journal Article
• Authors: Hewett, Yvonne; Ghimire, Subash; Farooqi, Bilal; Shah, Binay K
• Is Part Of: Journal of oncology pharmacy practice. Volume 24:Number 1(2018)
• Page Start: 28
• Page End: 32
• Publication Date: 2018-01
• Subjects: Differentiated thyroid cancer -- lenvatinib -- tyrosine kinase inhibitor; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155216680119
• Languages: English
• ISSNs: 1078-1552

Abstract

Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer.